Business Context and Reporting Period
This Form 8-K Current Report was filed by Viking Therapeutics, Inc. on September 28, 2017. The filing details the entry into material definitive agreements with Lincoln Park Capital Fund, LLC ("LPC") to secure future financing options.
Key Financial Metrics and Transaction Details
- Immediate Capital Raise: The Company sold 701,282 shares of Common Stock to LPC at approximately $1.78 per share, generating aggregate proceeds of $1,250,000.
- Future Financing Facility: Entered into an Equity Commitment Purchase Agreement allowing the Company to sell up to $15,000,000 in Common Stock to LPC over a 30-month period.
- Commitment Shares: Issued 100,000 shares of Common Stock to LPC as consideration for the commitment. No cash proceeds were received for these shares.
- Usage of Proceeds: Expected proceeds from future sales under the agreement are designated for working capital and general corporate purposes.
- Ownership Limit: LPC's beneficial ownership is capped at 4.99% of the Company's Common Stock.
Material Changes and Agreements
The primary material change is the establishment of a "Registered Offering Purchase Agreement" and a "Commitment Purchase Agreement." Unlike a standard fixed offering, the Commitment Purchase Agreement allows Viking Therapeutics to direct LPC to purchase shares at its sole discretion, subject to market price thresholds and a daily purchase limit of $1,000,000. The purchase price for future shares will be based on market prices at the time of purchase, with no upper price limit. The Company retains the right to terminate the agreement at any time without penalty.
Outlook, Risks, and Contingencies
- Market Dependency: Actual sales under the commitment depend on market conditions, the trading price of the Common Stock, and management's determination of funding needs.
- Short Selling Restrictions: LPC has covenanted not to engage in direct or indirect short selling or hedging of the Common Stock.
- Variable Rate Transaction Prohibition: The Company is prohibited from entering into a "Variable Rate Transaction" as defined in the agreement.
- Regulatory Status: The Commitment Shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the current trading price of Viking Therapeutics Common Stock relative to the $1.78 price paid in the initial tranche.
- Review the full text of the Commitment Purchase Agreement (Exhibit 10.2) to understand specific "threshold prices" and limitations on accelerated purchases.
- Confirm the total number of outstanding shares to assess the dilution impact of the 100,000 Commitment Shares and potential future issuances up to $15 million.
- Check subsequent filings to determine if the Company has exercised its right to sell shares under the 30-month commitment period.